# The Safety of Dapoxetine/Tadalafil Combination Therapy

> **NCT03177746** · PHASE4 · UNKNOWN · sponsor: **Neutec Ar-Ge San ve Tic A.Ş** · enrollment: 40 (estimated)

## Conditions studied

- Premature Ejaculation
- Erectile Dysfunction
- Safety Issues

## Interventions

- **DRUG:** Dapoxetine/Tadalafil 30/20 mg film coated tablet

## Key facts

- **NCT ID:** NCT03177746
- **Lead sponsor:** Neutec Ar-Ge San ve Tic A.Ş
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-31
- **Primary completion:** 2023-01-14
- **Final completion:** 2023-10-14
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03177746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03177746, "The Safety of Dapoxetine/Tadalafil Combination Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03177746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*